Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology (Nasdaq: VIR) reported Q1 2026 results and a corporate update on May 6, 2026. Key items: a closed global collaboration with Astellas for VIR-5500 with first patient dosed; positive Phase 2 SOLSTICE CHD results (77% HDV RNA TND at Week 72; 88% at Week 96 subset); $809.3M cash and investments as of March 31, 2026; net loss of $125.7M in Q1; cash runway to the second half of 2028.
Additional notes: completed $172.5M follow-on offering; Phase 3 ECLIPSE topline expected Q4 2026; complete Week 96 SOLSTICE data to be presented at EASL May 27-30, 2026.
Vir Biotechnology (Nasdaq: VIR) announced that CEO Marianne De Backer will appear in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on May 12, 2026 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas.
A live webcast will be available at the company's investor site and archived for 30 days.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Wednesday, May 6, 2026 at 4:30 p.m. ET / 1:30 p.m. PT to provide a corporate update and discuss financial results for the quarter ended March 31, 2026. The call is accessible via the company's Events & Presentations web page.
Vir Biotechnology (Nasdaq: VIR) closed its global collaboration and licensing agreement with Astellas on April 16, 2026, after the Hart-Scott-Rodino waiting period expired. The deal advances VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer.
Key financial terms: Vir received a $240 million upfront, a $75 million equity investment at $10.36/share, a near-term $20 million milestone, will split U.S. profit/loss 50/50, and is eligible for up to $1.37 billion in milestones plus tiered double-digit ex-U.S. royalties; certain proceeds will be shared with Sanofi.
Vir Biotechnology (Nasdaq: VIR) announced the first patient dosed in a Phase 1 dose-expansion cohort evaluating VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for metastatic prostate cancer (NCT05997615) on April 13, 2026.
The monotherapy expansion in late-line mCRPC will test a selected Q3W 800/2000/3500 µg/kg step-up dosing after Phase 1 dose-escalation data showed a favorable safety profile and promising anti-tumor activity presented at ASCO in February 2026. Combination expansion cohorts with an ARPI are expected to dose in the coming months ahead of planned pivotal Phase 3 trials in 2027.
Vir Biotechnology (Nasdaq: VIR) said management will participate in three investor conferences in March 2026: TD Cowen (fireside chat Mar 2, 3:10 p.m. ET), Leerink Partners (fireside chat Mar 10, 1:40 p.m. ET), and Barclays (one-on-one meetings Mar 12).
Live webcasts of the fireside chats will be available at the company investor website and archived for 30 days.
Summary not available.
Vir Biotechnology (Nasdaq: VIR) announced a proposed underwritten public offering of $200,000,000 of common stock, with a 30-day underwriter option to purchase up to an additional $30,000,000 of shares. All shares will be offered by Vir and the offering is subject to market conditions and SEC filings.
Goldman Sachs, Leerink Partners, Evercore ISI and Barclays are book-running managers. The shares are being offered under an automatically effective Form S-3 registration filed November 3, 2023.
Vir Biotechnology (Nasdaq: VIR) reported Q4 and full-year 2025 results and provided a corporate update on Feb 23, 2026. Key developments include a global collaboration with Astellas for PSMA-targeted TCE VIR-5500, updated Phase 1 VIR-5500 data showing favorable safety and anti-tumor activity, and $781.6 million in cash and investments as of Dec 31, 2025.
Pipeline and commercial moves include a Norgine license for tobevibart+elebsiran in select regions and upcoming Phase 3 plans for VIR-5500 in 2027.
Vir Biotechnology (Nasdaq: VIR) reported updated Phase 1 dose-escalation results for VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager in metastatic castration-resistant prostate cancer (mCRPC).
In 58 monotherapy patients there were no dose-limiting toxicities, manageable Grade ≥3 treatment-related adverse events in 12% (7/58), dose-dependent anti-tumor activity in ≥3,000 µg/kg cohorts (PSA50 82%, PSA90 53%) and RECIST objective responses of 45% (5/11); registrational trial planned for 2027.